Collagen Or Derivative Affecting Or Utilizing Patents (Class 514/17.2)
  • Patent number: 10898510
    Abstract: Disclosed is grade 2 sulphated hyaluronic acid having 2 to 60% molar, preferably 15 to 35%, and even more preferably between 20 and 25%, of the carboxyl groups functionalized with dopamine conjugated directly via an amide bond or by means of a spacer having an amino group for the formation of an amide bond with the carboxyl groups of hyaluronic acid and of a carboxyl group for the formation of an amide bond with the amino group of dopamine.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: January 26, 2021
    Assignee: FIDIA FARMACEUTICI S. P. A.
    Inventors: Cristian Guarise, Stefano Pluda, Devis Galesso
  • Patent number: 10890586
    Abstract: A method for assaying endoglycosidase activity includes providing a proteoglycan having a glycosaminoglycan chain with a non-reducing end; treating the proteoglycan with a glycosyltransferase to incorporate a carbohydrate into the non-reducing end of the glycosaminoglycan chain, wherein the carbohydrate includes a click chemistry moiety; adding a label to the proteoglycan, wherein the label includes a click chemistry moiety that reacts to the click chemistry moiety of the carbohydrate such that the label attaches to the carbohydrate to form a labeled proteoglycan; immobilizing the labeled proteoglycan on a multi-well plate, wherein the multi-well plate includes a specific anti-proteoglycan antibody for binding the labeled proteoglycan; treating the labeled proteoglycan with an endoglycosidase specific to the glycosaminoglycan chain; and detecting the labeled proteoglycan.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: January 12, 2021
    Assignee: BIO-TECHNE CORPORATION
    Inventors: Zhengliang L. Wu, Xinyi Huang, Cheryl M. Ethen
  • Patent number: 10850006
    Abstract: The present invention relates to protein biocoacervates and biomaterials and the methods of making and using protein biocoacervates and biomaterials. More specifically the present invention relates to protein biocoacervates and biomaterials that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, coated medical devices (e.g. stents, valves . . . ), vessels, tubular grafts, vascular grafts, wound healing devices including protein suture biomaterials and biomeshes, dental plugs and implants, skin/bone/tissue grafts, tissue fillers, protein biomaterial adhesion prevention barriers, cell scaffolding and other biocompatible biocoacervate or biomaterial devices.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: December 1, 2020
    Assignee: PETVIVO HOLDINS, INC.
    Inventors: David B. Masters, Eric P. Berg
  • Patent number: 10709810
    Abstract: The present disclosure provides tissue products produced from adipose-containing tissues, as well as methods for producing such tissue products. The tissue products can include decellularized and partially de-fatted tissues. In addition, the present disclosure provides systems and methods for using such products.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: July 14, 2020
    Assignee: LifeCell Corporation
    Inventors: Wenquan Sun, Xianghong Liu
  • Patent number: 10611822
    Abstract: Degradable bioprostheses made of collagen-based material having amine-based and ester-based crosslinks are provided, as are methods for their formation and use. Some embodiments of the present invention are directed towards a method of controlling the ratio of amine-based crosslinks to ester-based crosslinks within a collagen-based material to provide a tailorably crosslinked collagen-based material. Some embodiments provide a method of making a degradable bioprosthesis involving controlling crosslinking to afford a degradable bioprosthesis that is partially crosslinked. By controlling the ratio of amine-based to ester-based crosslinks, by controlling the level of crosslinking, or by controlling both of these features, degradable bioprostheses with tailored degradation rates can be synthesized. Some embodiments of degradable bioprostheses have degradation rates that are tailored to allow their use in particular medical applications.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: April 7, 2020
    Assignee: Harbor MedTech, Inc.
    Inventors: W. Jerry Mezger, Keith E. Myers
  • Patent number: 10426850
    Abstract: The present invention provides both a caged collagen mimetic peptide (CCMP) having the formula: L-S-Zm-[Gly-X-Y]n-LGly-X-Y-[Gly-X-Y]n (SEQ ID NO: 19); wherein L is one or more detectable moieties; S is one or more spacer molecules; Zm is any amino acid where m is an integer of 1 to 10; X is proline or modified proline; Y is proline or modified proline; Gly is glycine; n is an integer from 1 to 20; and LGly is a glycine covalently linked to a cage moiety comprising a labile protecting group, as well as a collagen mimetic peptides lacking the labile protecting group (CMP). The inventions are useful for binding collagen and denatured collagen and/or gelatin both in vitro and in vivo, and are useful for targeting any organ or tissue where collagen is present, and can be used for research and diagnostic imaging (both in vivo and in vitro) and also for in vivo therapeutic applications.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: October 1, 2019
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Michael S. Yu, Yang Li, Daniel Summerfield, Allen Yi-Lan Wang, Catherine A. Foss, Martin G. Pomper
  • Patent number: 10272059
    Abstract: The present invention relates to compositions containing, as active ingredient, a mixture of amino acids able to stimulate the biosynthesis of elastin and collagen.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: April 30, 2019
    Assignee: Professional Dietetics S.P.A.
    Inventor: Paolo Giorgetti
  • Patent number: 10058496
    Abstract: A thermosensitive ionic composite having a multistage phase transition characteristic, a method for preparing the thermosensitive ionic composite, and a biodegradable composition containing the thermosensitive ionic composite are provided.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: August 28, 2018
    Assignee: Research & Business Foundation Sungkyunkwan University
    Inventor: Yong Taik Lim
  • Patent number: 10031093
    Abstract: The invention relates to a radiation-induced radical species characterized in that it has, when measuring a biological nail, hair, or stratum corneum tissue sample by continuous wave EPR spectroscopy at ambient temperature: a Lande factor of 2.004; during Q band measurements at ambient temperature, a minimum signal intensity and a maximum signal intensity, said intensities being reached for magnetic field values separated by 1.8 mT; during X band measurements, a signal forming a singlet; and at the highest frequency, a signal having Lande factor anisotropy. The invention also relates to methods suitable for the identified radical species and intended for preparing a sample, analyzing the measured signal, and estimating a received dose.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: July 24, 2018
    Assignee: Institut de Radioprotection et de Sûreté Nucléaire
    Inventor: François Trompier
  • Patent number: 9827281
    Abstract: A method for treating cancer is disclosed by boiling blended cannabis material with oil and collecting oil infused with cannabis; targeting cancerous cells in a body; and injecting the oil infused with cannabis into the body portion with cancerous cells.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: November 28, 2017
    Inventor: Shabana Naheed
  • Patent number: 9764005
    Abstract: Methods of using fibrillar proteins are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment in vitro. In addition, rVP1 can significantly suppress murine and human breast cancer metastasis and human prostate and ovarian cancer metastasis in vivo while F-HSA can significantly suppress murine breast cancer metastasis.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: September 19, 2017
    Assignee: Academia Sinica
    Inventors: Shu-Mei Liang, Ching-Feng Chiu, Shao-Wen Hung, Jei-Ming Peng, Chi-Ming Liang
  • Patent number: 9732125
    Abstract: Polypeptide particles of the present invention are particles of a polypeptide derived from spider silk proteins, and have an average particle size of 1000 nm or less. A method for producing polypeptide particles of the present invention includes: a solution production step in which the polypeptide is dissolved in at least one solvent selected from the group consisting of DMSO, DMF, and these with an inorganic salt, so as to obtain a solution of the polypeptide; a step in which the solution produced in the solution production step is substituted with a water-soluble solvent so as to obtain an aqueous solution of the polypeptide; and a step in which the aqueous solution of the polypeptide is dried. Thereby, the present invention provides polypeptide particles suitable for application to a living body and capable of being applied to cosmetics, etc., while identifying the properties of the polypeptide particles, and a method for producing the same.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: August 15, 2017
    Assignee: SPIBER INC.
    Inventors: Toshiaki Osawa, Keisuke Morita
  • Patent number: 9539217
    Abstract: The present invention provides, among other things, nanoparticle compositions including a plurality of nanoparticles, each of which is comprised of a biodegradable or biocompatible polymer arranged in a nanoparticle structure defining an internal lumen and an external surface and one or more of a preparation of hydrophilic cellular components and a preparation of hydrophobic cellular components. In some embodiments, the preparation of hydrophilic cellular components is encapsulated within the internal lumen and the preparation of hydrophobic cellular components is associated with the external surface. Various methods of making and using disclosed nanoparticle compositions are also provided.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: January 10, 2017
    Assignee: Allertein Therapeutics, LLC
    Inventors: Howard Sosin, Michael Caplan, Tarek Fahmy
  • Patent number: 9446166
    Abstract: The invention relates to tissue adhesives or sealants, more specifically to fibrinogen based sealants reinforced with particulate material and chemically cross-linked. More particularly, the present invention is directed to tissue sealant, adhesive, hemostat, or scaffolding material containing thrombin, fibrinogen, a biocompatible particulate material having amine functionality, and a biocompatible polymer containing aldehyde groups. The present invention is also directed to methods for the use of such materials.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: September 20, 2016
    Assignee: Ethicon, Inc.
    Inventor: Chetan Anirudh Khatri
  • Patent number: 9403895
    Abstract: Improved methods are provided for the recombinant synthesis of collagen, particularly collagen VII, in host cell, and for therapeutic delivery of the same. The recombinant collagen is produced in a host cell that has increased levels of prolyl-4-hydroxylase, relative to basal cell levels. The collagen produced by the methods of the invention has increased numbers of modified proline residues, relative to a recombinant collagen produced in a host cell having basal levels of prolyl-4-hydroxylase. The increased proline modification provides for a collagen having increased stability, including increased in vivo stability.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: August 2, 2016
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States of America as Represented by the Department of Veterans Affairs
    Inventors: M. Peter Marinkovich, Alfred T. Lane, Jayakumar Rajadas
  • Patent number: 9370536
    Abstract: The present disclosure provides tissue products produced from adipose-containing tissues, as well as methods for producing such tissue products. The tissue products can include decellularized and partially de-fatted tissues. In addition, the present disclosure provides systems and methods for using such products.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: June 21, 2016
    Assignee: LifeCell Corporation
    Inventors: Wenquan Sun, Xianghong Liu
  • Patent number: 9238688
    Abstract: Disclosed is a compound which exhibits a higher effect of preventing wrinkle formation, a higher effect of improving wrinkles, a higher effect of making the skin beautiful, and a higher effect of improving skin quality than conventional retinol and retinol derivatives in a sustained manner. Further disclosed are a method for producing the same, and an external composition for the skin and a sheet-shaped cosmetic each containing the same as an active ingredient. More specifically disclosed are retinol-modified collagen in which a dicarboxylic acid is attached to at least one hydroxyl group of collagen and retinol is attached to a carboxyl group of at least one attached dicarboxylic acid, a method for producing the same, and an external composition for the skin and a sheet-shaped cosmetic each containing the same as an active ingredient.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: January 19, 2016
    Assignees: NATIONAL UNIVERSITY CORPORATION NARA INSTITUTE OF SCIENCE AND TECHNOLOGY, SUNSTAR INC.
    Inventors: Masao Tanihara, Kana Takaichi, Mariko Maeda, Tsukasa Mitsui, Kazushi Yamamoto, Akiko Hirano
  • Patent number: 9220691
    Abstract: The present invention relates to a transdermal therapeutic system for applying the active ingredient norelgestromin onto the skin, optionally in combination with estrogens. It further relates to the use of such systems for hormonal contraception, and for hormone replacement therapy.
    Type: Grant
    Filed: October 10, 2007
    Date of Patent: December 29, 2015
    Assignee: LTS LOHMANN THERAPIE SYSTEME AG
    Inventors: Frank Theobald, René Eifler
  • Patent number: 9220808
    Abstract: Degradable bioprostheses made of collagen-based material having amine-based and ester-based crosslinks are provided, as are methods for their formation and use. Some embodiments of the present invention are directed towards a method of controlling the ratio of amine-based crosslinks to ester-based crosslinks within a collagen-based material to provide a tailorably crosslinked collagen-based material. Some embodiments provide a method of making a degradable bioprosthesis involving controlling crosslinking to afford a degradable bioprosthesis that is partially crosslinked. By controlling the ratio of amine-based to ester-based crosslinks, by controlling the level of crosslinking, or by controlling both of these features, degradable bioprostheses with tailored degradation rates can be synthesized. Some embodiments of degradable bioprostheses have degradation rates that are tailored to allow their use in particular medical applications.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: December 29, 2015
    Assignee: HARBOR MEDTECH, INC.
    Inventors: W. Jerry Mezger, Keith E. Myers
  • Patent number: 9149512
    Abstract: A collagen mixture having a portion of unhydrolyzed eggshell membrane collagen and Avian collagen.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: October 6, 2015
    Assignee: Molecular Biology International, Inc.
    Inventor: Robert den Hoed
  • Patent number: 9131713
    Abstract: In order to provide a product that is suitable as fat substitute in foods, which can be produced simply and inexpensively and is deemed safe from the nutritional physiology viewpoint and with which the typical texture of fat-containing foods can be simulated as favorably as possible, particles of collagen material are proposed which are substantially insoluble and swellable in water, wherein in swollen state the particles have an average diameter of less than approximately 150 ?m. A process for the production of this product is additionally proposed.
    Type: Grant
    Filed: January 27, 2011
    Date of Patent: September 15, 2015
    Assignee: GELITA AG
    Inventors: Eberhard Dick, Simone Walter
  • Patent number: 9132207
    Abstract: A composition suitable for use as replacement material for all or part of a disc nucleus during percutaneous injection, the composition comprising: an injectable, curable, cross-linkable, non-immunogenic non-toxic protein hydrogel that (i) the protein component of the protein hydrogel contains at least one crosslinkable amino acid (ii) has a static compressive modulus of at least about 10 kPa, and (iii) has a dynamic compressive modulus of at least about 10 kPa; an iodinated contrast solution comprising an amount of an iodine compound sufficient to increase radiopacity to a discernable level, wherein the solution causes a decrease in the static and/or dynamic compressive modulus; and an amount of a crosslinker sufficient to restore at least about 100% of the decrease in static and/or dynamic compressive modulus caused by addition of the iodinated contrast solution.
    Type: Grant
    Filed: October 27, 2009
    Date of Patent: September 15, 2015
    Assignee: SPINE WAVE, INC.
    Inventors: Ulrich Berlemann, Thomas G. Wilson, Peter Wronski, Thomas Douville
  • Patent number: 9044455
    Abstract: Described are purified extracellular matrix materials isolated from the abdominal wall of animals and including the subserous fascia layer of the abdominal wall. Such medical materials can find use in treating damaged tissue and in certain aspects in providing tissue support for the repair of hernias. Related methods of manufacture and use are also described.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: June 2, 2015
    Assignee: Cook Biotech Incorporated
    Inventors: Bhavin Shah, Katie L. Harrigan
  • Patent number: 9040484
    Abstract: Improved methods are provided for the recombinant synthesis of collagen, particularly collagen VII, in host cell, and for therapeutic delivery of the same. The recombinant collagen is produced in a host cell that has increased levels of prolyl-4-hydroxylase, relative to basal cell levels. The collagen produced by the methods of the invention has increased numbers of modified proline residues, relative to a recombinant collagen produced in a host cell having basal levels of prolyl-4-hydroxylase. The increased proline modification provides for a collagen having increased stability, including increased in vivo stability.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: May 26, 2015
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Department of Veterans Affairs
    Inventors: M. Peter Marinkovich, Alfred T. Lane, Jayakumar Rajadas
  • Publication number: 20150140064
    Abstract: Nano scale collagen particles can be obtained from an embrittling and attrition process that reduces the size of collagen particles to the nano scale. These nano scale collagen particles have many favorable properties such as providing beneficial and enhanced properties for cell seeding and wound healing. The nano scale collagen particles can be included in biocompatible (e.g., biostable or biodegradable) compositions and are useful for wound treatment and management, as well as in cell cultures and tissue engineering implants.
    Type: Application
    Filed: January 27, 2015
    Publication date: May 21, 2015
    Applicant: EMPIRE TECHNOLOGY DEVELOPMENT LLC
    Inventors: Hengky CHANG, Henry LEUNG
  • Publication number: 20150126454
    Abstract: A composition that is useful in a skin function improving agent includes at least two of the following: vitamin K, a sapogenol, and a collagen hydrolysate. This composition can be used in a skin function improving agent and is particularly useful in a skin function improving agent for inhibiting transdermal moisture loss and/or for retaining the moisture in the stratum corneum.
    Type: Application
    Filed: January 14, 2015
    Publication date: May 7, 2015
    Inventors: Shuichi KAMO, Toshiro SATO, Rumi KAWAHARA, Shunsuke SUZUKI
  • Publication number: 20150126453
    Abstract: Tissue products lacking a desired percentage of immunogenic epitopes, such as galactose alpha-1,3 galactose epitopes, are provided. Methods of making and using the tissue products are also provided.
    Type: Application
    Filed: November 4, 2014
    Publication date: May 7, 2015
    Inventors: Hui Xu, Li Ting Huang, Hua Wan, Rick T. Owens, Nathaniel Bachrach
  • Patent number: 9023619
    Abstract: The invention concerns non-natural Gly-Xaa-Yaa-protein monomers and non-natural Gly-Xaa-Yaa-proteins comprising or consisting of multimers of the monomers. The non-natural Gly-Xaa-Yaa-proteins can be produced with enhanced monodispersity.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: May 5, 2015
    Assignee: Fujifilm Manufacturing Europe B.V.
    Inventor: Arjo De Boer
  • Publication number: 20150119335
    Abstract: The present invention relates to a method of treating exercise-induced joint pain in arthritis-free mammals by the administration of undenatured Type II collagen.
    Type: Application
    Filed: January 13, 2014
    Publication date: April 30, 2015
    Applicant: Interhealth Nutraceuticals, Inc.
    Inventors: Paul Dijkstra, Francis C. Lau, James Lugo, Zainulabedin M. Saiyed
  • Patent number: 9012406
    Abstract: Disclosed herein are compositions comprising gelatin, collagen, and a chromophore that produces a reactive oxygen species upon exposure to electromagnetic radiation. These compositions have also been found to be strong tissue adhesives that crosslinks the composition and tissue and are effective in closing and sealing wounds, fixation of grafts/implants and anastomoses.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: April 21, 2015
    Assignee: Conversion Energy Enterprises, Inc.
    Inventors: Barbara A. Soltz, Robert Soltz
  • Patent number: 9011929
    Abstract: The present invention relates to a composition for cartilaginous tissue repair and to a production method therefor. The present invention comprises the steps of: (a) dissolving freeze-dried fibrinogen in an aprotinin solution; (b) dissolving freeze-dried thrombin in a stabilizing solution; (c) mixing an enriched collagen solution with thrombin and the stabilizing solution; and installing the fibrinogen solution (a) to one side of a dual kit and the solution (c) containing the collagen to the other side, and then mixing and injecting into damaged cartilaginous tissue. In the present invention, which is constituted as described above, biomaterials such as collagen and fibrin are mixed so as to allow damaged cartilaginous tissue to be repaired to a state allowing transplantation onto the tissue, and efficient regeneration is induced, thereby making it possible to reduce surgery-related stress on people and animals while inducing relatively rapid and efficient cartilage repair and regeneration.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: April 21, 2015
    Assignee: Sewon Cellontech Co., Ltd.
    Inventors: Hyun-Shin Park, Ji-Chul Yu, Ju-Hee Park, Jang-Hoon Kim, Hun Kim, Sae-Bom Lee, Jae-Deog Jang, Cheong-Ho Jang
  • Publication number: 20150105323
    Abstract: The present disclosure provides an engineered collagen composition comprising collagen, wherein the collagen composition is compressed to form a gradient of at least one physical property. Methods of using and of manufacturing the engineered collagen compositions of the present disclosure are also provided.
    Type: Application
    Filed: October 16, 2014
    Publication date: April 16, 2015
    Inventors: Tyler NOVAK, Kevin BLUM, Corey NEU, Sherry VOYTIK-HARBIN
  • Patent number: 9006182
    Abstract: A light activated collagen-flavin composite layer incorporating riboflavin is applied as treatment for infected lesions. These composites have also been found to be strong tissue adheives that are effective in closing and sealing wounds, fixation of grafts/ implants and anastomoses. Advantages include speed of closure, reduced infection due to the elimination of foreign matter, evidence of accelerated wound healing and the ease of use in complex surgery, especially when watertight seals, limited access or small repair size are important factors. The riboflavin in the collagen layer is exposed to light (e.g., light having a wavelength between 360-375 nm or 440-480 nm), decomposing the riboflavin to form reactive oxygen species (ROS). Strong crosslinks between the collagen composite and tissue results. In addition, similar exposures eradicate pathogens in the wound.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: April 14, 2015
    Assignee: Conversion Energy Enterprises, Inc.
    Inventors: Barbara A. Soltz, Robert Soltz
  • Patent number: 9006193
    Abstract: Provided herein are polymeric carriers suitable for the delivery of polynucleotides (e.g. oligonucleotides) and/or other therapeutic agents into a living cell.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: April 14, 2015
    Assignees: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Craig L. Duvall, Danielle Benoit, Robert W. Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E. E. Paschal, Charbel Diab, Priyadarsi De
  • Publication number: 20150094266
    Abstract: Compositions include synergistic combinations of xyloglucans and vegetable or animal proteins that are useful in the treatment of intestinal disorders or of disorders originating from the intestinal system and transferred to other systems, such as the genitourinary system. The compositions include xyloglucans or an extract containing xyloglucans, and one or more animal or vegetable proteins. Methods for the treatment or prevention of intestinal disorders are provided, including prevention of diarrhoea.
    Type: Application
    Filed: December 10, 2014
    Publication date: April 2, 2015
    Applicant: Novintethical Pharma, SA
    Inventors: Marco Di Fulvio, Miguel Angel Alonso, Michele Giuseppe Di Schiena
  • Publication number: 20150080815
    Abstract: A wound dressing makes use of a polysaccharide, such as Manuka honey, in combination with collagen in order to suppress the efficacy of matrix metalloproteinases enzymes (“MMPs”) present in chronic wounds. The mixture is applied to an absorbent surface that is designed to absorb the mixed polysaccharide only partially.
    Type: Application
    Filed: September 19, 2013
    Publication date: March 19, 2015
    Applicant: MEDLINE INDUSTRIES, INC.
    Inventors: Debashish Chakravarthy, Andrew J. Ford
  • Publication number: 20150079143
    Abstract: Methods of making a biologically active three-dimensional scaffold capable of supporting growth and differentiation of a cell are described. Biologically active three-dimensional scaffold made by the methods of the invention and an engineered tissue made from the scaffolds are described. Fibers of desired porosity can be obtained from non-structural ECM by lyophilization and/or electrospinning which can be useful for numerous tissue engineering applications requiring complex scaffolds, such as wound healing, artificial skin (burns), soft tissue replacement/repair and spinal cord injury.
    Type: Application
    Filed: November 18, 2014
    Publication date: March 19, 2015
    Inventors: Peter I. Lelkes, Mengyan Li, Anat Perets, Honesto Poblete, Philip Lazarovici
  • Patent number: 8980835
    Abstract: A chemically modified water-soluble elastin that is obtained by subjecting to N-acylating some or all of the primary amines and secondary amines contained in the molecule of a high molecular weight water-soluble elastin and coupling some or all of the carboxyl groups contained in the molecule with the amino group of an amino acid alkyl ester. A chemically modified water-soluble elastin/collagen mixed gel obtained by mixing a collagen with a chemically modified water-soluble elastin that is obtained by subjecting to N-acylating some or all of the primary amines and secondary amines contained in the molecule of a high molecular weight water-soluble elastin and coupling some or all of the carboxyl groups contained in the molecule with the amino group of an amino acid alkyl ester.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: March 17, 2015
    Assignee: Kyushu Institute of Technology
    Inventors: Kouji Okamoto, Hiroshi Yamada, Yosuke Maegawa, Ryota Watanabe, Mitsuhiro Adachi
  • Publication number: 20150072007
    Abstract: The present invention relates to a non-invasive medical therapy and a composition for avoiding organ transplantation, or controlling biological rejection of transplanted organs, or treating organs under consideration for replacement by transplant, and otherwise treating aged, diseased and/or abnormal tissues and/or organs. More specifically, the non-invasive medical therapy involves administering to a patient an elemental nutritional feeding comprising a free amino acid profile simulating and/or replicating a targeted diseased or transplanted tissue and/or organ. The subject invention provides methods of inactivating reactive component epitopes of moieties pathogenic substances or producing immunogenic compositions containing pathogenic substances comprising contacting pathogenic substances, or compositions containing pathogenic substances, with super critical carbon dioxide or liquid nitrogen. Similar benefits are produced using high HLB surfactants also reducing carcinogenic factors.
    Type: Application
    Filed: September 11, 2014
    Publication date: March 12, 2015
    Inventor: LEONARD S. GIRSH
  • Publication number: 20150071877
    Abstract: A method for preparing a bioactive composition containing conditioned cell culture medium is disclosed. The method comprises culturing cells of two or more eukaryotic cell line to form conditioned culture media, separating the cultured cells from the conditioned culture media, and combining conditioned culture media to form a bioactive composition. Novel bioactive compositions, formulations and their use in treating of a variety of diseases and health conditions are also disclosed.
    Type: Application
    Filed: November 12, 2014
    Publication date: March 12, 2015
    Inventors: Greg Maguire, Peter Friedman
  • Publication number: 20150064147
    Abstract: Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a collagen component.
    Type: Application
    Filed: November 6, 2014
    Publication date: March 5, 2015
    Applicant: Allergan, Inc.
    Inventors: Jacob F. Pollock, Lauren E. Kokai, CUNQI Cui, Xiaojie Yu, Dennis E. Van Epps, Darin J. Messina
  • Publication number: 20150065429
    Abstract: Degradable bioprostheses made of collagen-based material having amine-based and ester-based crosslinks are provided, as are methods for their formation and use. Some embodiments of the present invention are directed towards a method of controlling the ratio of amine-based crosslinks to ester-based crosslinks within a collagen-based material to provide a tailorably crosslinked collagen-based material. Some embodiments provide a method of making a degradable bioprosthesis involving controlling crosslinking to afford a degradable bioprosthesis that is partially crosslinked. By controlling the ratio of amine-based to ester-based crosslinks, by controlling the level of crosslinking, or by controlling both of these features, degradable bioprostheses with tailored degradation rates can be synthesized. Some embodiments of degradable bioprostheses have degradation rates that are tailored to allow their use in particular medical applications.
    Type: Application
    Filed: October 29, 2014
    Publication date: March 5, 2015
    Inventors: W. Jerry Mezger, Keith E. Myers
  • Publication number: 20150065430
    Abstract: The process for manufacturing collagen and trace elements from sea water consists of various steps which are raw material preparation, resting of raw material, preliminary filtration to remove heavy metals, deodorize and purity remaining impurities, spraying of water, separation of heavy metals, collagen and trace elements from water and separation of collagen and trace elements. The process according to this invention, apart from sea water, can be applied to other type of salt water by adjusting the salinity and density of the water to an optimal value. The process according to this invention yields clean and purified collagen which is easily absorbed by human body and contains numerous types of trace elements.
    Type: Application
    Filed: November 7, 2014
    Publication date: March 5, 2015
    Inventors: Yongsheng Qiu, Hain-Ken Wang
  • Patent number: 8968716
    Abstract: Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over conventional bioadhesive hydrogels in terms of biocompatibility. In addition, the in situ-forming bioadhesive hydrogel has excellent biocompatibility and mechanical strength and has excellent tissue adhesiveness thanks to modification with/without dopa derivatives. The hydrogel finds a variety of applications in the biomedical field, including bioadhesives or hemostats, implant substances for tissue regeneration and augmentation, carriers for delivering biologically active materials or drugs, etc.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: March 3, 2015
    Assignee: Ajou University Industry-Academic Cooperation Foundation
    Inventors: Ki-Dong Park, Yoon-Ki Joung, Kyung-Min Park, Eu-Gene Lih
  • Publication number: 20150057230
    Abstract: The present invention relates to a biotin-conjugated hexapeptide-2 derivative or a pharmaceutically acceptable salt thereof and use thereof. More particularly, the present invention relates to a biotin-conjugated hexapeptide-2 derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, a composition including the same as an active ingredient, and a method for improving wrinkles and inhibiting skin aging using the same.
    Type: Application
    Filed: March 27, 2013
    Publication date: February 26, 2015
    Inventors: Kee-Don Park, Chae-Jin Lim, Seok-Jeong Yoon, Seon-Deok Kwon
  • Patent number: 8961929
    Abstract: It is an object of the present invention to provide a targeting agent, which enables the delivery of a drug to tumor sites or the imaging of tumor sites by utilizing its effect of accumulating to such tumor sites. The present invention provides a targeting agent for tumor site, which comprises a hydrophilic polymer-modified carrier coated with a gelatin-like protein that has repeats of a sequence represented by Gly-X-Y characteristic to collagen and has two or more sequences of cell adhesion signals in a single molecule wherein X and Y each independently represent an amino acid and a plurality of Gly-X-Y sequences may be the same or different.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: February 24, 2015
    Assignee: FUJIFILM Corporation
    Inventors: Kazutaka Ogiwara, Makoto Ohno, Masayoshi Kojima, Masayuki Kawakami, Chihaya Kakinuma, Tasuku Sasaki, Kiyohito Takada
  • Publication number: 20150038423
    Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. Methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. In addition, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.
    Type: Application
    Filed: February 11, 2013
    Publication date: February 5, 2015
    Inventors: Tulasi Ponnapakkam, Sagaya Theresa Leena Philominathan, Joshua Sakon, Ranjitha Katikaneni, Takaki Koide, Osamu Matsushita, Robert C. Gensure
  • Publication number: 20150038424
    Abstract: A bioadhesive formulation, comprising gelatin, alginate and a coupling agent, capable of forming a bioadhesive matrix, which is characterized by rapid curing, optimal viscosity, high bonding strength, flexibility, biocompatibility and biodegradability, is disclosed. Further disclosed is such a bioadhesive formulation which further comprises a bioactive agent, and a drug-eluting bioadhesive matrix formed therefrom, the bioadhesive matrix being capable of delivering the bioactive agent to a bodily site. Methods utilizing the bioadhesive formulations and matrices in various biological and medical procedures are also disclosed.
    Type: Application
    Filed: February 14, 2013
    Publication date: February 5, 2015
    Inventors: Meital Zilberman, Adaya Shefy-Peleg, Binyamin Cohen, Maytal Foox
  • Publication number: 20150038425
    Abstract: This invention relates to collagen-binding synthetic peptidoglycans. More particularly, this invention relates to collagen-binding synthetic peptidoglycans for use in vascular intervention procedures. The invention also relates to kits comprising such collagen—binding synthetic peptidoglycans and catheters or stents.
    Type: Application
    Filed: September 2, 2014
    Publication date: February 5, 2015
    Inventors: John E. Paderi, Alyssa Panitch, Kinam Park, Katherine Stuart
  • Patent number: 8946163
    Abstract: The disclosure describes collagen constructs comprising anticancer agents, preferably, platinum, and related methods.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: February 3, 2015
    Assignee: MiMedx Group, Inc.
    Inventor: Thomas J. Koob